176 related articles for article (PubMed ID: 34798905)
1. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database.
Vallabhaneni S; Adusumalli S; Wu J; Groeneveld PW; Gerson J; O'Quinn RP
Cardiooncology; 2024 Jun; 10(1):33. PubMed ID: 38824606
[TBL] [Abstract][Full Text] [Related]
3. Arrhythmia Patterns in Patients on Ibrutinib.
Fazal M; Kapoor R; Cheng P; Rogers AJ; Narayan SM; Wang P; Witteles RM; Perino AC; Baykaner T; Rhee JW
Front Cardiovasc Med; 2021; 8():792310. PubMed ID: 35047578
[No Abstract] [Full Text] [Related]
4. Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors.
Wei C; Fazal M; Loh A; Kapoor R; Gomez SE; Shah S; Rogers AJ; Narayan SM; Wang PJ; Witteles RM; Perino AC; Cheng P; Rhee JW; Baykaner T
J Interv Card Electrophysiol; 2024 Jan; 67(1):111-118. PubMed ID: 37256462
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.
Onitilo AA; Piwuna TO; Islam N; Furuya-Kanamori L; Kumar S; Doi SAR
Clin Med Res; 2022 Mar; 20(1):16-22. PubMed ID: 35022197
[No Abstract] [Full Text] [Related]
6. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
[TBL] [Abstract][Full Text] [Related]
7. Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Khalid S; Yasar S; Khalid A; Spiro TP; Haddad A; Daw H
Cureus; 2018 May; 10(5):e2701. PubMed ID: 30062075
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib-related atrial fibrillation: A single center Australian experience.
Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
[TBL] [Abstract][Full Text] [Related]
9. Arrhythmogenic Cardiotoxicity Associated With Contemporary Treatments of Lymphoproliferative Disorders.
Sherazi S; Schleede S; McNitt S; Casulo C; Moore JE; Storozynsky E; Patel A; Vidula N; Aktas MK; Zent CS; Goldenberg I
J Am Heart Assoc; 2023 Mar; 12(6):e025786. PubMed ID: 36892046
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors.
Aghel N; Baro Vila RC; Lui M; Hillis C; Leong DP
Curr Cardiol Rep; 2023 Sep; 25(9):941-958. PubMed ID: 37498449
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
Lentz R; Feinglass J; Ma S; Akhter N
Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
[TBL] [Abstract][Full Text] [Related]
12. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
[TBL] [Abstract][Full Text] [Related]
13. Advanced electrophysiologic mapping systems: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2006; 6(8):1-101. PubMed ID: 23074499
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
15. High incidence of atrial fibrillation in patients treated with ibrutinib.
Baptiste F; Cautela J; Ancedy Y; Resseguier N; Aurran T; Farnault L; Escudier M; Ammar C; Gaubert M; Dolladille C; Barraud J; Peyrol M; Cohen A; Paganelli F; Alexandre J; Ederhy S; Thuny F
Open Heart; 2019; 6(1):e001049. PubMed ID: 31168393
[TBL] [Abstract][Full Text] [Related]
16. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Sestier M; Hillis C; Fraser G; Leong D
Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
[TBL] [Abstract][Full Text] [Related]
17. Elevated cardiovascular risk and acute events in hospitalized colon cancer survivors: A decade-apart study of two nationwide cohorts.
Desai R; Mondal A; Patel V; Singh S; Chauhan S; Jain A
World J Clin Oncol; 2024 Apr; 15(4):548-553. PubMed ID: 38689632
[TBL] [Abstract][Full Text] [Related]
18. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study.
Banks E; Joshy G; Korda RJ; Stavreski B; Soga K; Egger S; Day C; Clarke NE; Lewington S; Lopez AD
BMC Med; 2019 Jul; 17(1):128. PubMed ID: 31266500
[TBL] [Abstract][Full Text] [Related]
19. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
20. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
